Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin

One of the most feared repercussions of type 2 diabetes mellitus is the risk of adverse cardiovascular outcomes. The current antidiabetic agents on the market have had difficulty in showing cardiovascular outcome improvement. The EMPA-REG OUTCOME trial studied the sodium-glucose cotransporter 2 inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanon, Vani P, Patel, Shalin, Sanon, Saurabh, Rodriguez, Ruben, Pham, Son V, Chilton, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422533/
https://www.ncbi.nlm.nih.gov/pubmed/28496330
http://dx.doi.org/10.2147/TCRM.S97619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5422533/
https://www.ncbi.nlm.nih.gov/pubmed/28496330
http://dx.doi.org/10.2147/TCRM.S97619

Ejemplares similares